Already AAV vectors are being tested in clinical trials to reduce production of pathologic proteins resulting from GoTF mutations for ALS (AAVrh10-antisense-SOD1) and HD (AAV5-miHTT). This evidence concerns the gene SOD1 and Huntington disease.